Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-07 07:00 |
Press Release: Dupixent® (dupilumab) application for treatment of chronic spont…
|
English | PDF • 143.6 KB | ||
| 2023-03-07 07:00 |
Communiqué de presse: Dupixent® (dupilumab) : la FDA accepte d’examiner la dema…
|
French | PDF • 156.9 KB | ||
| 2023-03-06 17:57 |
6-K
|
English | ZIP • 28.0 KB | ||
| 2023-03-02 08:00 |
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTU…
|
English | PDF • 169.8 KB | ||
| 2023-03-02 08:00 |
Communiqué de presse: L’étude XTEND-Kids de phase III, désormais clôturée, a dé…
|
French | PDF • 168.2 KB | ||
| 2023-02-24 23:20 |
6-K
|
English | ZIP • 48.7 KB | ||
| 2023-02-24 17:16 |
ALTUVIIIO™ approuvé par la FDA américaine : cet événement positif déclenche une…
|
French | PDF • 195.6 KB | ||
| 2023-02-24 17:16 |
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment re…
|
English | PDF • 183.2 KB | ||
| 2023-02-24 17:07 |
Document d'enregistrement Universel 2022
|
French | ZIP • 8.7 MB | ||
| 2023-02-24 17:07 |
Document d'enregistrement Universel 2022
|
French | ZIP • 8.7 MB | ||
| 2023-02-24 16:56 |
IRANNOTICE
|
English | ZIP • 12.7 KB | ||
| 2023-02-24 16:31 |
Communiqué de presse: La présentation de nouvelles données de phase III au WORL…
|
French | PDF • 216.8 KB | ||
| 2023-02-24 16:31 |
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazy…
|
English | PDF • 209.9 KB | ||
| 2023-02-24 16:25 |
20-F
|
English | ZIP • 30.6 MB | ||
| 2023-02-24 16:07 |
Annual Report 2022 Form 20F
|
English | PDF • 9.3 MB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
